Wells Fargo’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-20,192
| Closed | -$201K | – | 7241 |
|
|
2025
Q2 | $201K | Buy |
20,192
+3,196
| +19% | +$25.7K | ﹤0.01% | 4768 |
|
|
2025
Q1 | $101K | Buy |
16,996
+352
| +2% | +$2.58K | ﹤0.01% | 5096 |
|
|
2024
Q4 | $128K | Buy |
16,644
+2,402
| +17% | +$20.6K | ﹤0.01% | 5061 |
|
|
2024
Q3 | $145K | Buy |
14,242
+2,811
| +25% | +$42.9K | ﹤0.01% | 4788 |
|
|
2024
Q2 | $170K | Buy |
11,431
+1,400
| +14% | +$20.1K | ﹤0.01% | 4623 |
|
|
2024
Q1 | $137K | Buy |
10,031
+2,358
| +31% | +$25.7K | ﹤0.01% | 4707 |
|
|
2023
Q4 | $84K | Sell |
7,673
-13,940
| -64% | -$138K | ﹤0.01% | 5011 |
|
|
2023
Q3 | $237K | Sell |
21,613
-3,748
| -15% | -$47.9K | ﹤0.01% | 4252 |
|
|
2023
Q2 | $336K | Buy |
25,361
+793
| +3% | +$11.3K | ﹤0.01% | 4238 |
|
|
2023
Q1 | $334K | Buy |
24,568
+23,855
| +3,346% | +$427K | ﹤0.01% | 4110 |
|
|
2022
Q4 | $13.9K | Sell |
713
-1,511
| -68% | -$29.5K | ﹤0.01% | 5417 |
|
|
2022
Q3 | $42K | Sell |
2,224
-221
| -9% | -$5.09K | ﹤0.01% | 5031 |
|
|
2022
Q2 | $51K | Sell |
2,445
-357
| -13% | -$8.47K | ﹤0.01% | 5007 |
|
|
2022
Q1 | $89K | Sell |
2,802
-5,555
| -66% | -$202K | ﹤0.01% | 5383 |
|
|
2021
Q4 | $390K | Sell |
8,357
-51,544
| -86% | -$1.72M | ﹤0.01% | 4863 |
|
|
2021
Q3 | $1.62M | Buy |
59,901
+59,685
| +27,632% | +$1.56M | ﹤0.01% | 3854 |
|
|
2021
Q2 | $5K | Sell |
216
-1,658
| -88% | -$39.5K | ﹤0.01% | 6340 |
|
|
2021
Q1 | $64K | Sell |
1,874
-5,937
| -76% | -$215K | ﹤0.01% | 5697 |
|
|
2020
Q4 | $264K | Sell |
7,811
-92
| -1% | -$2.44K | ﹤0.01% | 4932 |
|
|
2020
Q3 | $195K | Buy |
+7,903
| New | +$213K | ﹤0.01% | 4975 |
|
Other funds holding ITOS
Wells Fargo's ITOS Position: Q3 2025 in Review
Wells Fargo sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 20,192 shares — an estimated $201K sold.
Wells Fargo first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $1.62M in Q3 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Wells Fargo reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 20,192 iTeos Therapeutics shares in Q3 2025, an estimated $201K.
- Wells Fargo first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Wells Fargo's iTeos Therapeutics position peaked at $1.62M in Q3 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.